Get the Stockscreener App
4.79
3.23%
-0.16
Monte Rosa Therapeutics Inc stock is traded at $4.79, with a volume of 578.53K.
It is down -3.23% in the last 24 hours and up +3.90% over the past month.
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.
See More
Previous Close:
$4.95
Open:
$4.85
24h Volume:
578.53K
Relative Volume:
1.32
Market Cap:
$294.63M
Revenue:
-
Net Income/Loss:
$-130.41M
P/E Ratio:
-2.1384
EPS:
-2.24
Net Cash Flow:
$-67.76M
1W Performance:
-15.52%
1M Performance:
+3.90%
6M Performance:
-28.08%
1Y Performance:
+9.61%
1-Day Range:
$4.78
$4.97
1-Week Range:
$4.78
$5.774
52-Week Range:
$3.5001
$12.40
Monte Rosa Therapeutics Inc Stock (GLUE) Company Profile
Name
Monte Rosa Therapeutics Inc
Sector
Industry
Phone
617-949-2643
Address
321 HARRISON AVENUE, BOSTON
Compare GLUE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GLUE
Monte Rosa Therapeutics Inc
|
4.79 | 304.47M | 0 | -130.41M | -67.76M | -2.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Monte Rosa Therapeutics Inc Stock (GLUE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-19-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-15-24 | Initiated | Wedbush | Outperform |
| Jan-03-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-13-22 | Initiated | UBS | Buy |
| Aug-15-22 | Initiated | Jefferies | Buy |
| Apr-28-22 | Initiated | Credit Suisse | Neutral |
| Feb-10-22 | Initiated | Wells Fargo | Equal Weight |
| Oct-14-21 | Initiated | SVB Leerink | Mkt Perform |
View All
Monte Rosa Therapeutics Inc Stock (GLUE) Latest News
Statistical indicators supporting Monte Rosa Therapeutics Inc.’s strengthHigh Conviction Stock Long-Term Summary - Newser
Sector ETF performance correlation with Monte Rosa Therapeutics Inc.Price Movement and Market Sentiment Analysis - Newser
GLUE’s Stock Market Adventure: 19.49% YTD Growth Amidst Volatility - investchronicle.com
Will Monte Rosa Therapeutics Inc. bounce back from current supportFree Chart Breakout Buy Signal Detection - Newser
How to integrate Monte Rosa Therapeutics Inc. into portfolio analysis toolsEarnings Based Stock Performance Forecast - Newser
What makes Monte Rosa Therapeutics Inc. stock price move sharplyLow Risk High Return Opportunities Identified - metal.it
Real time scanner hits for Monte Rosa Therapeutics Inc. explainedBuy Signal System Based on Price Action - Newser
Monte Rosa Therapeutics Inc. Rebound Backed by Sentiment Shift - metal.it
How does Monte Rosa Therapeutics Inc. generate profit in a changing economyFree Stock Recommendation With Proven Results - jammulinksnews.com
Can Monte Rosa Therapeutics Inc. Regain Lost Ground This QuarterLow Risk High Return Opportunities Identified - metal.it
Monte Rosa Therapeutics Inc. Company Revenue and Profit Trends: A Deep DiveShort Term Risk Controlled Alerts - metal.it
Should you hold or exit Monte Rosa Therapeutics Inc. nowMonthly Long-Term Market Recap and Summary - Newser
Sector ETF performance correlation with Monte Rosa Therapeutics Inc. Daily Entry Opportunity Forecasting Tool - Newser
Monte Rosa Therapeutics Inc. Enters Reversal Setup in Weekly ChartsReal-Time Market Sentiment Tracking Gains Momentum - beatles.ru
Real time scanner hits for Monte Rosa Therapeutics Inc. explained Chart Pattern Recognition for Profit Timing - Newser
What institutional investors are buying Monte Rosa Therapeutics Inc. stockConsistent wealth multiplication - jammulinksnews.com
Is Monte Rosa Therapeutics Inc. a Top Dividend Stock to Watch in 2025Consistent Win Signals - metal.it
Why Monte Rosa Therapeutics Inc. stock attracts strong analyst attention Free Accurate Buy Point for Momentum Stocks - Newser
What are the technical indicators suggesting about Monte Rosa Therapeutics Inc.Consistent high-yield stocks - jammulinksnews.com
What are the latest earnings results for Monte Rosa Therapeutics Inc.High-return market picks - jammulinksnews.com
How strong is Monte Rosa Therapeutics Inc. company’s balance sheetRemarkably fast returns - jammulinksnews.com
Why Monte Rosa Therapeutics Inc. stock attracts strong analyst attentionFree Financial Group - Newser
How Monte Rosa Therapeutics Inc. stock performs during market volatilityFree Access to Community - Newser
What analysts say about Monte Rosa Therapeutics Inc. stockOverwhelming profit margins - Autocar Professional
What drives Monte Rosa Therapeutics Inc. stock priceFree Trend-Following Techniques - Autocar Professional
Is Monte Rosa Therapeutics Inc. a good long term investmentFree Trading Strategy Suggestions - Autocar Professional
Monte Rosa Therapeutics Inc. Stock Analysis and ForecastPhenomenal wealth increase - jammulinksnews.com
Monte Rosa Therapeutics Announces First Subjects Dosed in - GlobeNewswire
Monte Rosa Therapeutics and the Breakthrough Potential of MRT-8102 in Inflammatory Disease Treatment - AInvest
Monte Rosa begins phase 1 trial of NEK7-targeting molecular glue degrader - Investing.com
Monte Rosa begins phase 1 trial of NEK7-targeting molecular glue degrader By Investing.com - Investing.com South Africa
Monte Rosa Therapeutics Inc Stock (GLUE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):